These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 8329715

  • 1. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
    Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ.
    Blood; 1993 Jul 15; 82(2):600-5. PubMed ID: 8329715
    [Abstract] [Full Text] [Related]

  • 2. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
    Leopold LH, Shore SK, Newkirk TA, Reddy RM, Reddy EP.
    Blood; 1995 Apr 15; 85(8):2162-70. PubMed ID: 7718886
    [Abstract] [Full Text] [Related]

  • 3. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
    Okabe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni-Eda Y, Kurosawa M, Miyazaki T.
    Blood; 1992 Sep 01; 80(5):1330-8. PubMed ID: 1515646
    [Abstract] [Full Text] [Related]

  • 4. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W, Daskalakis M, Finke J, Dölken G.
    FEBS Lett; 1994 Jan 31; 338(2):175-8. PubMed ID: 8307177
    [Abstract] [Full Text] [Related]

  • 5. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
    Okabe M, Kunieda Y, Miyagishima T, Kobayashi M, Kurosawa M, Itaya T, Sakurada K, Miyazaki T.
    Leuk Lymphoma; 1993 Jul 31; 10(4-5):307-16. PubMed ID: 7693103
    [Abstract] [Full Text] [Related]

  • 6. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L, Wilson SB, Milliken S, Biggs J, Kearney P.
    Exp Hematol; 1993 Dec 31; 21(13):1714-8. PubMed ID: 8243570
    [Abstract] [Full Text] [Related]

  • 7. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH, Shore SK, Reddy EP.
    Leuk Lymphoma; 1996 Aug 31; 22(5-6):365-73. PubMed ID: 8882949
    [Abstract] [Full Text] [Related]

  • 8. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y, Chen YZ, Huang HF, Chen P, Lu LH.
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep 31; 35(9):859-63. PubMed ID: 12958661
    [Abstract] [Full Text] [Related]

  • 9. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan 31; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec 31; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 11. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B.
    Blood; 1995 Jul 15; 86(2):726-36. PubMed ID: 7606002
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
    Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D.
    J Clin Invest; 2007 Sep 15; 117(9):2408-21. PubMed ID: 17717597
    [Abstract] [Full Text] [Related]

  • 14. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK, Nabissa PM, Reddy EP.
    Oncogene; 1993 Nov 15; 8(11):3183-8. PubMed ID: 8414522
    [Abstract] [Full Text] [Related]

  • 15. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T, Szczylik C, Malaguarnera L, Calabretta B.
    Folia Histochem Cytobiol; 1991 Nov 15; 29(3):85-9. PubMed ID: 1794439
    [Abstract] [Full Text] [Related]

  • 16. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
    Honda H, Oda H, Suzuki T, Takahashi T, Witte ON, Ozawa K, Ishikawa T, Yazaki Y, Hirai H.
    Blood; 1998 Mar 15; 91(6):2067-75. PubMed ID: 9490692
    [Abstract] [Full Text] [Related]

  • 17. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, Calabretta B, Mensink EJ.
    Leukemia; 1994 Jan 15; 8(1):129-40. PubMed ID: 8289478
    [Abstract] [Full Text] [Related]

  • 18. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH, Shore SK, Newkirk T, Mangan K, Reddy EP.
    Prog Clin Biol Res; 1994 Jan 15; 389():175-82. PubMed ID: 7700900
    [No Abstract] [Full Text] [Related]

  • 19. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
    Snyder DS, Wu Y, McMahon R, Yu L, Rossi JJ, Forman SJ.
    Biol Blood Marrow Transplant; 1997 Oct 15; 3(4):179-86. PubMed ID: 9360779
    [Abstract] [Full Text] [Related]

  • 20. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH, Wu SC, Chen WS, Yen CC, Yang MH, Tsai YC, Chen PM.
    Biochem Biophys Res Commun; 2004 Jun 04; 318(3):764-72. PubMed ID: 15144904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.